Stock Detail
ARIAD PHARMACEUTICALS INC
Sector: Drugs
Latest Quote @ Mon May 5 11:21:47 (15 min delayed)
| $16.66 |
$16.67 |
$16.73 |
+0.06 |
0.36% |
|
Last Day's Data
| $16.67 |
$16.85 |
$0.20 |
1.21% |
0.00 |
$16.47 |
| $16.63 |
$16.40 |
3.00 |
3.07B |
2.89M |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 17.09 |
16.88 |
16.64 |
16.43 |
16.19 |
Stock Profile
ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines to treat cancer by regulating cell signaling with small molecules. Its lead cancer product candidate, AP23573, is an mTOR inhibitor to treat solid tumors and hematologic malignancies. AP23573 is in multiple Phase II and Ib clinical trials as a single agent in patients with hematologic malignancies and solid tumors. Two multicenter Phase Ib studies with AP23573 in combination with other anti-cancer therapies, which are underway in Europe, focus primarily on patients with breast, ovarian, non-small-cell lung, and prostate cancers, as well as certain sarcomas. ARIAD also has an exclusive license to technology and patents related to certain NF-kB treatment methods, as well as the discovery, development, and use of drugs to regulate NF-kB cell-signaling activity, which might be useful in treating certain diseases. In addition, the company has a partnership with Medinol, Ltd., a cardiovascular medical device company, to develop and commercialize stents and other medical devices to deliver AP23573 to prevent reblockage of injured vessels following stent-assisted angioplasty, a common nonsurgical procedure for dilating or opening narrowed arteries. ARIAD was founded in 1991 by Harvey J. Berger and is headquartered in Cambridge, Massachusetts.
